The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients
Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classifi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/157437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179173869420544 |
|---|---|
| author | Wen-Sheng Liu Yueh-Lin Wu Szu-Yuan Li Wu-Chang Yang Tzen-Wen Chen Chih-Ching Lin |
| author_facet | Wen-Sheng Liu Yueh-Lin Wu Szu-Yuan Li Wu-Chang Yang Tzen-Wen Chen Chih-Ching Lin |
| author_sort | Wen-Sheng Liu |
| collection | DOAJ |
| description | Objectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classified by their response at two different timings. First, patients whose hematocrit (Hct) increased 1.5% in the first week were defined as initial responders (IR, n=16). We compared several parameters between IR and the rest of the study subjects (non-IR, n=45). Second, patients whose Hct increased 2% in the 4th week were defined as sustained responders (SR, n=12), and we did a similar comparison. Results. The Hct showed a waveform fluctuation. Compared with the rest, IR had significantly lower platelet counts and higher levels of ferritin, total protein, total bilirubin, and serum sodium, while SR had significantly lower levels of C-reactive protein and low-density lipoprotein (All P<0.05). In comparison with the rest, higher Hct persisted for 10 weeks in SR but only for two separate weeks (the 1st and 7th week) in IR. Conclusions. The initial and sustained erythropoietic responses are independent from each other and are associated with different factors. Treatment focusing on these factors may improve the response. |
| format | Article |
| id | doaj-art-bc6a44296c3941fcb3963f621bf9df3a |
| institution | OA Journals |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-bc6a44296c3941fcb3963f621bf9df3a2025-08-20T02:18:33ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/157437157437The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis PatientsWen-Sheng Liu0Yueh-Lin Wu1Szu-Yuan Li2Wu-Chang Yang3Tzen-Wen Chen4Chih-Ching Lin5School of Medicine, National Yang-Ming University, Taipei 112, TaiwanSchool of Medicine, National Yang-Ming University, Taipei 112, TaiwanSchool of Medicine, National Yang-Ming University, Taipei 112, TaiwanSchool of Medicine, National Yang-Ming University, Taipei 112, TaiwanDivision of Nephrology, Department of Medicine, Taipei Medical Univeristy Hospital, Taipei 110, TaiwanSchool of Medicine, National Yang-Ming University, Taipei 112, TaiwanObjectives. Erythropoiesis-stimulating agents (ESA) are the main treatment for anemia in hemodialysis (HD) patients. We evaluated factors determining the response after treatment of a new ESA (continuous erythropoietin erythropoietin receptor activator (CERA)). Methods. 61 HD patients were classified by their response at two different timings. First, patients whose hematocrit (Hct) increased 1.5% in the first week were defined as initial responders (IR, n=16). We compared several parameters between IR and the rest of the study subjects (non-IR, n=45). Second, patients whose Hct increased 2% in the 4th week were defined as sustained responders (SR, n=12), and we did a similar comparison. Results. The Hct showed a waveform fluctuation. Compared with the rest, IR had significantly lower platelet counts and higher levels of ferritin, total protein, total bilirubin, and serum sodium, while SR had significantly lower levels of C-reactive protein and low-density lipoprotein (All P<0.05). In comparison with the rest, higher Hct persisted for 10 weeks in SR but only for two separate weeks (the 1st and 7th week) in IR. Conclusions. The initial and sustained erythropoietic responses are independent from each other and are associated with different factors. Treatment focusing on these factors may improve the response.http://dx.doi.org/10.1100/2012/157437 |
| spellingShingle | Wen-Sheng Liu Yueh-Lin Wu Szu-Yuan Li Wu-Chang Yang Tzen-Wen Chen Chih-Ching Lin The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients The Scientific World Journal |
| title | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
| title_full | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
| title_fullStr | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
| title_full_unstemmed | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
| title_short | The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients |
| title_sort | waveform fluctuation and the clinical factors of the initial and sustained erythropoietic response to continuous erythropoietin receptor activator in hemodialysis patients |
| url | http://dx.doi.org/10.1100/2012/157437 |
| work_keys_str_mv | AT wenshengliu thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT yuehlinwu thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT szuyuanli thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT wuchangyang thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT tzenwenchen thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT chihchinglin thewaveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT wenshengliu waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT yuehlinwu waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT szuyuanli waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT wuchangyang waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT tzenwenchen waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients AT chihchinglin waveformfluctuationandtheclinicalfactorsoftheinitialandsustainederythropoieticresponsetocontinuouserythropoietinreceptoractivatorinhemodialysispatients |